3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
7
Endometrial Neoplasms
4
Lymphedema
3
Neoplasms
2
Melanoma
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Suspected Central Nervous System Tumors
1
Stomach Neoplasms
1
Skull Base Neoplasms
1
Pediatric Patients With Solid Tumors
1
Mixed Tumor, Mesodermal
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholecystitis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
Indocyanine Green
×
Clear all
No trials found.